Roth MKM Reiterates Buy on Tenax Therapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jonathan Aschoff has reiterated a Buy rating on Tenax Therapeutics (NASDAQ:TENX) and maintained a $30 price target.
February 20, 2024 | 4:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roth MKM analyst Jonathan Aschoff reiterates a Buy rating on Tenax Therapeutics with a maintained $30 price target.
The reiteration of a Buy rating and maintenance of a $30 price target by a reputable analyst like Jonathan Aschoff suggests a strong vote of confidence in Tenax Therapeutics. This endorsement is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100